<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444390</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0105/1403</org_study_id>
    <nct_id>NCT02444390</nct_id>
  </id_info>
  <brief_title>Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor</brief_title>
  <acronym>SAFIR-TOR</acronym>
  <official_title>Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation ARC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective biomarker study to show that p4EBP1 staining predicts clinical benefit
      from treatment with everolimus in patients who are eligible for everolimus+exemestane
      treatment. This trial is not aimed at evaluating a drug activity. Everolimus and exemestane
      are prescribed within their approved indication as per usual practice and are not part of
      this trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estrogen hormone receptor-positive metastatic breast cancer who failed to non steroidal
      aromatases inhibitors in patients who are eligible for everolimus+exemestane treatment
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 19, 2015</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the predictive value of p4EBP1 for an mTOR inhibitor efficacy</measure>
    <time_frame>from inclusion up to 6 months</time_frame>
    <description>The primary endpoint of the trial is the predictive value of p4EBP1 for an mTOR inhibitor efficacy, measured by the association between expression level of the biomarker (high vs low expression with a cutoff value set at the median percentages of marked cells) and clinical benefit after 6 months of everolimus+exemestane treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Exemestane+everolimus</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Exemestane+everolimus are administered as per their approved indication</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>biopsy of a metastasis</description>
    <arm_group_label>Exemestane+everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Eligible for everolimus+exemestane treatment as required by the marketing authorisation
        conditions

          1. Women (or men) with histologically-proven Estrogen Receptor-positive (ER+) and/or
             Progesterone Receptor-positive (PR+) / Human Epidermal growth factor Receptor
             2-negative (HER2-) metastatic breast adenocarcinoma or locally advanced disease who
             cannot be treated with surgery and/or radiation therapy

          2. Postmenopausal women

          3. Asymptomatic if visceral disease

          4. Second line hormonotherapy or more for metastatic or locally advanced disease after
             recurrence or progression following a non-steroidal aromatase inhibitor (in adjuvant
             or metastatic setting)

             - Eligible for the biopsy

          5. Progressive disease under endocrine therapy at the time of inclusion

          6. Treatment with everolimus and exemestane not yet started

          7. Patients with metastases that can be biopsied, except bone metastases

          8. Measurable or evaluable disease

          9. Age ≥18 years

         10. WHO Performance Status 0/1

         11. Provision of signed and dated, written informed consent prior to any protocol specific
             procedure, including biopsy

         12. Patient with social insurance coverage

        Exclusion Criteria:

          1. Contraindications for everolimus+exemestane treatment

          2. Previous treatment with an anti-mTOR therapy

          3. More than 1 previous line of chemotherapy in metastatic setting

          4. Life expectancy &lt;3 months

          5. Spinal cord compression and/or symptomatic or progressive brain metastases (unless
             asymptomatic or treated and stable off steroids for at least 30 days prior to start of
             study drug)

          6. Haematopoietic function or organ impairment as shown by the following criteria:

               -  Polynuclear neutrophils &lt;1.5 x 10⁹/L

               -  Platelets &lt;100 x 10⁹/L

               -  Haemoglobin &lt;90 g/L

               -  Alanine aminotransferase (ALAT) / aspartate aminotransferase (ASAT) &gt; 2.5 x ULN
                  in the absence of or &gt;5 x upper limit of normal (ULN) in the presence of liver
                  metastases

               -  Bilirubin &gt;1.5 x ULN

               -  Creatinine clearance ≤50 mL/min (measured or calculated by Cockcroft and Gault
                  formula)

               -  Calcium and phosphate &gt;ULN

          7. Abnormal coagulation or any other medical situation contraindicating biopsy

          8. Bone metastases when this is the only site of biopsiable disease

          9. Any condition which in the Investigator's opinion makes it undesirable for the subject
             to participate in the trial or which would jeopardize compliance with the protocol

         10. Individuals deprived of liberty or placed under the authority of a tutor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bachelot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard, Lyon, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest/Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest/Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSTITUT DE CANCEROLOGIE Lucien Neuwirth</name>
      <address>
        <city>St PRIEST EN JAREZ</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Failed non steroidal aromatases inhibitors</keyword>
  <keyword>Eligible for everolimus+exemestane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02444390/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

